The New York legal cannabis market size was valued at US$ 2.35 billion in 2025 and is projected to grow to 2.79 billion in 2026. Forecasts suggest it will reach approximately US$ 13.05 billion by 2035, registering a CAGR of 18.7% during the period.
Firstly, the New York legal cannabis market is termed as the regulated provision, application, & retail of marijuana for adults 21 and older, which was signed into law under the Marihuana Regulation & Taxation Act (MRTA). Certain major catalysts are impacting the overall progression across the market, such as strengthening retail access, where the Office of Cannabis Management (OCM) has licensed numerous applications across the supply chain. This significantly surges the number of operational dispensaries & optimizing consumer access. Alongside, New York’s licensing landscape consciously prefers justice-involved individuals, minorities, women-owned businesses, & service-disabled veterans, which fosters more varied entrepreneurs into the legal area.
Emerging technological breakthroughs across the New York legal cannabis market cover the utilization of proprietary enterprise resource planning (ERP) platforms by operators to monitor every product from cultivation through distribution to retail. Moreover, the New York framework is promoting regulated packaging with scannable QR codes that connect consumers to lab-testing data. Also, buyers can ensure batch potency, product origins, & safety screenings for pesticides & heavy metals. Eventually, entrepreneurs are representing expedited progression in ancillary services, such as specialized cannabis real estate, regulatory compliance consulting, packaging, tech platforms, security, & lab testing. New York City is increasingly focusing on launches of legal consumption lounges where patrons can have regulated products on-site.
Gradually, the market is leveraging advanced AI solutions, such as CannAdvisor AI & CannabisRegulations.ai, to assist businesses in managing compliance by tracking seed-to-sale data, reconciling inventory against state databases, & flagging discrepancies before regulators address them. Ongoing advances in interactive, AI-enabled wellness platforms are supporting customers in executing cannabis strains & effects based on their personal preferences. Subsidiary, gen AI is spurring drafting of Standard Operating Procedures (SOPs) & simplifying business applications for prospective growers, processors, & retail operators.
Promoting Social & Economic Equity
In this era, New York is massively preferring restorative justice, while over half of all active adult-use licenses, like cultivators, processors, & retailers, have passed to Social and Economic Equity (SEE) & CAURD (Conditional Adult-Use Retail Dispensary) applicants.
Spurring Diversity of Product
The leading players are actively transitioning beyond traditional flower & pre-rolls, with substantial expansion predicted in cannabis-infused beverages, low-dose edibles, & wellness products customized to a widespread, mainstream audience.
Prominent Enforcement
Specifically, the state Office of Cannabis Management (OCM) & local law enforcement continue to implement crackdowns & shop closures, though legal pushback & due-process bottlenecks have declined, toward the complete destruction of these unlicensed shops.
| Table | Scope |
| Market Size in 2026 | USD 2.79 Billion |
| Projected Market Size in 2035 | USD 13.05 Billion |
| CAGR (2026 - 2035) | 18.7% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Product Type, By Cannabis Type, By Source, By Application, By Distribution Channel, By Consumer Age Group, By End User |
| Top Key Players | RISE Dispensary, The Travel Agency, Highvendor, Silly Nice, Curaleaf Holdings, Ayrloom, Cresco Labs Inc. |
| Segment | Share 2025 (%) |
| Flower | 42% |
| Edibles | 24% |
| Concentrates | 12% |
| Vaporizers | 11% |
| Tinctures | 4% |
| Topicals | 4% |
| Capsules & Softgels | 3% |
The Flower Segment Led the Market in 2025
In 2025, the flower segment held a 42.0% share of the New York legal cannabis market. Dominance is driven by possession of numerous state-licensed dispensaries that offer locally grown, tested flowers & legal delivery. New York is massively facilitating adults & patients to access regulated, lab-tested flower that confirms product safety, predictable potency, & peace of mind.
However, the edibles segment captured a 24.00% share in 2025 & is estimated to show rapid growth. Day by day, new consumers are heavily favouring smoke-free products, which raises the demand for edibles. Alongside impressive product innovations are improvements in taste & dosage control in these products. Another advantage is that they offer accurate dosing, extreme discretion, & an extended, calming body high that often lasts up to 12 hours.
The concentrates segment held a notable share of 12.00% in 2025, due to experienced users seeking higher potency products. Additionally, many premium extracts are acquiring shelf space. Coupled with emerging technological extraction optimizations, the quality of the products. The adoption of advanced extraction methods enables the experience of the authentic, full-spectrum flavor profile of craft cannabis strains without inhaling combusted plant material.
On the other hand, the vaporizers segment accounted for an 11.00% share of the New York legal cannabis market. The growth is fueled by discrete consumption surges and adoption. Alongside, product convenience is appealing to wider younger consumers, coupled with the use of portable devices, which fosters recurring demand.
| Segment | Share 2025 (%) |
| THC-Dominant | 68% |
| CBD-Dominant | 12% |
| Balanced THC/CBD | 20% |
The THC-Dominant Segment Dominated the Market in 2025
The THC-dominant segment led with a 68.0% share of the market in 2025. Drivers are escalating consumer desire for their potent psychoactive effects, & also, experienced consumers & patients are hugely prioritizing these products to control issues, such as pain, insomnia, & nausea. In terms of safety, the purchasing of this product offers protection against contaminants, including heavy metals, pesticides, & mold that are common in illegal street cannabis.
Whereas the balanced THC/CBD segment accounted for a 20.00% share in 2025 & is anticipated to expand rapidly in the New York legal cannabis market. Respective expansion is propelled by many users looking for controlled psychoactive effects, along with wellness markets that are widely adopting balanced formulations. Their immersive offerings encompass the higher use for everyday pain, inflammation relief, & stress reduction without eliminating heavy intoxication.
In 2025, the CBD-dominant segment held a 12.00% share of the New York legal cannabis market. Especially in the wellness applications, demand for this product is gradually increasing. The development of a legal retail footprint for hundreds of dispensaries has enabled consumers who earlier bought unauthenticated products to purchase safe, lab-tested, & consistent CBD-dominant products.
| Segment | Share 2025 (%) |
| Marijuana-Derived Cannabis | 87% |
| Hemp-Derived Cannabis | 13% |
The Marijuana-Derived Cannabis Segment Was Dominant in the Market in 2025
In 2025, the marijuana-derived cannabis segment captured a major share of 87.0% of the market. This mainly covers the origin from cannabis plants containing more than 0.3% Delta-9 THC, while these products can only be legally sold by state-licensed adult-use or medical dispensaries. The use of cannabinoids interacts with the body's endocannabinoid system to lower inflammation & change pain perception, providing relief for concerns such as arthritis or neuropathy.
Moreover, the hemp-derived cannabis segment captured a 13.00% share in 2025 & is estimated to grow fastest in the New York legal cannabis market. This explores procurement from industrial hemp plants containing 0.3% or less Delta-9 THC, which can be further synthetically converted or extracted to develop intoxicating or wellness products. Also, as hemp is federally authorized, hemp-derived products are more easily accessible & transportable across NY.
| Segment | Share 2025 (%) |
| Recreational Use | 72% |
| Medical Use | 20% |
| Wellness & Lifestyle | 8% |
The Recreational Use Segment Led the Market in 2025
The recreational use segment dominated with a 72.0% share of the market in 2025. The dominance is mainly driven by broader normalization, increased product availability, & major price declines. Alongside, consumers are also propelled by a desire for safely regulated products & the social equity mission behind state-licensed dispensaries.
The medical use segment captured the second-largest share of 20.00% of the market in 2025. Primarily, the expansion is fueled by physician acceptance that raises utilization, along with expanded qualifying conditions, which increase patient enrollment. Developing novel therapeutic research activities is also impacting the medical use of legal cannabis.
The wellness & lifestyle segment held an 8.00% share in 2025 and is predicted to expand fastest in the New York legal cannabis market. New York’s consumers are promoting the integration of cannabis into wellness routines. Whereas functional products are achieving popularity. However, innovative lifestyle branding is attracting new users.
| Segment | Share 2025 (%) |
| Individual Consumers | 81% |
| Registered Medical Patients | 12% |
| Hospitality & Cannabis Lounges | 4% |
| Research & Healthcare Institutions | 3% |
The Individual Consumers Segment Dominated the Market in 2025
In 2025, the individual consumers segment held a dominant share of 81.0% of the market. Widespread consumers are looking for legal retailers because it ensures products have gone through New York's testing standards for mold, pesticides, & heavy metals. Eventually, consumers are highly demanding the latest & diverse products, such as edibles, vapes, and infused beverages. Alongside prioritising legal stores that provide knowledgeable staff, seamless product education, & short wait times over the long hours traditionally offered by unlicensed sellers.
Although the registered medical patients segment captured a 12.00% share of the New York legal cannabis market. Major growth is propelled by sustaining therapeutic adoption by these patients. Also, rising clinical recommendations are encouraging the use of legal cannabis, while product consistency supports patient retention.
The hospitality & cannabis lounges segment held a 4.00% share in 2025 & is predicted to witness the fastest growth. Specifically, emerging consumption venues are appealing to visitors. Besides this, surging tourism-related demand & transformative regulatory evolution foster the overall growth. Involvement of the New York Office of Cannabis Management (OCM) highly favours market stability, launching consumption lounge regulations deliberately to assist licensed producers & retailers.
The research & healthcare institutions segment captured a 3.00% share in 2025 due to an increase in authorized clinical trials, rising funding for medical efficacy studies, and strict regulatory frameworks governing the use of cannabis in pharmaceutical research and university-level therapeutic development.
In 2025 & ongoing in 2026, New York’s regulatory framework has expanded padlocking authority, such as growth in the Fiscal Year 2025 Budget; the state ramped up multi-agency enforcement. Additionally, NY has raised consequences for property owners, which bring civil fines up to $200,000 for deliberately renting to illegal cannabis operators. In the last quarter of 2025, the CCB prolonged all provisional CAURD & adult-use licenses through December 31, 2026, granting operators extra time to preserve retail brick-and-mortar storefronts amidst real estate barriers.
R&D
Regulatory Approvals
Patient Support & Services
| Vendors | Offerings |
| RISE Dispensary | In October 2025, it inaugurated its 108th US location in Lebanon, Pennsylvania, that facilitate various kinds of cannabis products & supports local nonprofits. |
| The Travel Agency | Its offerings cover curated selections of local craft flower, pre-rolls, infused beverages, & various edible alternatives. |
| Highvendor | A company specialises in lab-tested flower & vaporized oils, with delivery services across different regions of the state. |
| Silly Nice | In February 2025, it broadened to over 100 licensed dispensaries across New York State & further expanded to over 150 locations spanning Manhattan, Brooklyn, the Bronx, Staten Island & Upstate New York. |
| Curaleaf Holdings | In May 2026, they continued their ‘Built for Growth’ strategy, reporting strong Q1 2026 results with $324 million in net revenue & empowering a robust balance sheet in anticipation of 280E tax relief. |
| Ayrloom | This majorly offers 2:1 THC to CBD sparkling waters, fast-acting gummies, vapes, & tinctures. |
| Cresco Labs Inc. | In June 2026, they announced the closing of a credit agreement with Needham Bank, a Massachusetts-based commercial bank, facilitating the Company with a US$50 million revolving credit facility. |
By Product Type
By Cannabis Type
By Source
By Application
By Distribution Channel
By Consumer Age Group
By End User
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
